Belzutifan, a HIF-2a Inhibitor, for von Hippel-Lindau (VHL) Disease-Associated Neoplasms: 36 Months of Follow-Up of the Phase 2 LITESPARK-004 Study
Belzutifan
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Belzutifan, a HIF-2a Inhibitor, for von Hippel-Lindau (VHL) Disease-Associated Neoplasms: 36 Months of Follow-Up of the Phase 2 LITESPARK-004 Study ### Output: Belzutifan